RNA干渉技術市場：タイプ別、治療薬別、用途別-2025-2030年の世界予測

RNA干渉技術市場の2023年の市場規模は329億2,000万米ドルで、2024年には392億5,000万米ドルに達すると予測され、CAGR 22.38％で成長し、2030年には1,354億米ドルに達すると予測されています。

RNA干渉（RNAi）技術は、分子生物学における革命的なツールであり、特定の遺伝子のサイレンシングを可能にし、遺伝子機能の研究や新規治療戦略の開発に強力な手段を提供します。その範囲は、基礎研究、創薬、治療への応用など多方面に及び、主に遺伝性疾患と後天性疾患に焦点を当てています。RNAiの必要性は、病気の原因となる遺伝子を正確に標的とするそのユニークな能力にあり、それによって個別化医療や、がん、ウイルス感染症、遺伝性疾患などの治療が期待できます。最終用途は製薬会社、バイオテクノロジー企業、学術研究機関など多岐にわたる。

RNAi技術の市場成長は、技術の進歩、慢性疾患の増加、個別化医療への関心の拡大から大きな影響を受けています。さらに、RNAi研究開発への多額の投資と、学術機関とバイオテクノロジー企業との共同研究が、技術革新の新たな扉を開いています。送達方法における最近の動向と、強力かつ選択的なsiRNAの開発は、臨床応用における大きな機会を提示しています。北米地域は強固なヘルスケアインフラと研究活動により現在リードしているが、アジア太平洋地域はヘルスケア投資の増加と遺伝子研究に対する政府資金の増加により大幅な成長が見込まれています。

しかし、RNAi分子の細胞質への送達課題、オフターゲット効果の可能性、生物学的環境における安定性向上の必要性など、市場はいくつかの限界に直面しています。さらに、規制上のハードルや高い開発コストは、市場の成長と普及にとって依然として大きな課題です。送達システムの強化、標的特異性の改善、より安全で効果的なRNAi送達のためのナノ粒子の利用に焦点を当てた革新は、研究開発の有望分野です。企業は、RNAiとCRISPRのような他の遺伝子編集技術との融合に投資して治療用途を拡大し、学術研究機関との提携を活用して、このダイナミックな市場でのイノベーションと採用を加速すべきです。

市場力学：急速に進化するRNA干渉技術市場の主要市場インサイトを公開

RNA干渉技術市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の遺伝性疾患および慢性疾患の有病率の上昇
  • 創薬・薬剤開発におけるRNAi技術の応用拡大
  • 分子診断のニーズの高まり
• 市場抑制要因
  • RNAi療法に関する厳しいFDA規制
• 市場機会
  • ナノテクノロジーとがんの分野における進行中の研究開発
  • 開発中の最先端のRNAi治療薬
• 市場の課題
  • RNA干渉療法のデリバリーにおける懸念

ポーターの5つの力：RNA干渉技術市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：RNA干渉技術市場における外部からの影響の把握

外部マクロ環境要因は、RNA干渉技術市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析RNA干渉技術市場における競合情勢の把握

RNA干渉技術市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスRNA干渉技術市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、RNA干渉技術市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 遺伝性疾患と慢性疾患の世界の増加
    • 創薬と開発におけるRNAi技術の応用拡大
    • 分子診断の必要性の高まり
  • 抑制要因
    • RNAi療法に関する厳格なFDA規制
  • 機会
    • ナノテクノロジーとがんの分野における進行中の研究開発
    • 開発中の最先端のRNAi療法
  • 課題
    • RNA干渉療法の実施に関する懸念
• 市場セグメンテーション分析
  • タイプ：さまざまな疾患の治療のための標的遺伝子治療におけるsiRNAの使用
  • アプリケーション：薬物の発見と開発のためのRNA干渉技術の急速な採用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 RNA干渉技術市場：タイプ別

• 二本鎖RNA
• マイクロRNA
• siRNA

第7章 RNA干渉技術市場セラピューティクス

• 自己免疫性肝炎
• B型肝炎とC型肝炎
• 神経疾患
• 腫瘍学
• 呼吸器疾患

第8章 RNA干渉技術市場：用途別

• 医薬品の発見と開発
• 治療薬

第9章 南北アメリカのRNA干渉技術市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のRNA干渉技術市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのRNA干渉技術市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • スイッチ・セラピューティクス、5,200万米ドルを調達して初のRNAi技術を開発
  • アルニラム・ファーマシューティカルズとメディソン・ファーマは、RNAi治療薬の商業化に向けて、協力関係を複数地域にわたるパートナーシップに拡大することを発表

企業一覧

• Gradalis, Inc.
• Arcturus Therapeutics Holdings Inc.
• Merck KGaA
• NeuBase Therapeutics, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Novartis AG
• Nutcracker Therapeutics, Inc.
• Bioneer Corporation
• Ionis Pharmaceuticals, Inc.
• Arbutus Biopharma Corporation
• AMSBIO
• Atalanta Therapeutics
• Phio Pharmaceuticals Corp.
• Thermo Fisher Scientific Inc.
• Sanofi S.A.
• AstraZeneca PLC
• Dicerna Pharmaceuticals, Inc.
• Sirnaomics, Inc.
• ProQR Therapeutics N.V.
• Silence Therapeutics PLC
• CureVac N.V.
• Alnylam Pharmaceuticals, Inc.
• Gotham Therapeutics Corp.

LIST OF FIGURES

• FIGURE 1. RNA INTERFERENCE TECHNOLOGY MARKET RESEARCH PROCESS
• FIGURE 2. RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RNA INTERFERENCE TECHNOLOGY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RNA INTERFERENCE TECHNOLOGY MARKET DYNAMICS
• TABLE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DSRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 32. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 49. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 52. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 104. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 116. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 119. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

The RNA Interference Technology Market was valued at USD 32.92 billion in 2023, expected to reach USD 39.25 billion in 2024, and is projected to grow at a CAGR of 22.38%, to USD 135.40 billion by 2030.

RNA interference (RNAi) technology is a revolutionary tool in molecular biology that enables the silencing of specific genes, thus providing a powerful means for studying gene function and developing novel therapeutic strategies. Its scope extends across multiple dimensions, including basic research, drug discovery, and therapeutic application, primarily focusing on genetic and acquired diseases. The necessity of RNAi lies in its unique ability to precisely target disease-causing genes, thereby offering promise in personalized medicine and treatment of conditions like cancer, viral infections, and genetic disorders. The tight end-use scope involves pharmaceuticals, biotechnology companies, and academic research institutions.

Market growth for RNAi technology is heavily influenced by technological advancements, increasing incidences of chronic diseases, and the expanding interest in personalized medicine. Additionally, substantial investments in RNAi research and development, along with collaborations between academic institutions and biotech firms, are opening new doors for innovation. Recent advancements in delivery methods and the development of potent and selective siRNAs present significant opportunities in clinical applications. The North American region is currently leading due to robust healthcare infrastructure and research activity, yet Asia-Pacific is expected to witness substantial growth due to rising healthcare investments and increased government funding for genetic research.

However, the market faces several limitations, such as delivery challenges of RNAi molecules into the cell cytoplasm, potential off-target effects, and the necessity for improved stability in biological settings. Furthermore, regulatory hurdles and high development costs remain significant challenges to market growth and widespread adoption. Innovations focusing on enhanced delivery systems, improved target specificity, and utilizing nanoparticles for safer and more effective RNAi delivery are promising areas for research and development. Companies should invest in merging RNAi with other gene-editing technologies like CRISPR to expand therapeutic applications and leverage partnerships with academic and research institutions to accelerate innovation and adoption in this dynamic market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RNA Interference Technology Market

The RNA Interference Technology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising Prevalence of Genetic and Chronic Disorders Globally
  • Increasing Application of RNAi Technology in Drug Discovery & Development
  • Growing Need for Molecular Diagnostics
• Market Restraints
  • Stringent FDA Regulations Regarding RNAi Therapies
• Market Opportunities
  • Ongoing Research and Development in the Field of Nanotechnology and Cancer
  • State-of-the-art RNAi Therapies in Development
• Market Challenges
  • Concerns in Delivery of RNA-Interference Therapies

Porter's Five Forces: A Strategic Tool for Navigating the RNA Interference Technology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RNA Interference Technology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RNA Interference Technology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RNA Interference Technology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RNA Interference Technology Market

A detailed market share analysis in the RNA Interference Technology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RNA Interference Technology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RNA Interference Technology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the RNA Interference Technology Market, highlighting leading vendors and their innovative profiles. These include Gradalis, Inc., Arcturus Therapeutics Holdings Inc., Merck KGaA, NeuBase Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Novartis AG, Nutcracker Therapeutics, Inc., Bioneer Corporation, Ionis Pharmaceuticals, Inc., Arbutus Biopharma Corporation, AMSBIO, Atalanta Therapeutics, Phio Pharmaceuticals Corp., Thermo Fisher Scientific Inc., Sanofi S.A., AstraZeneca PLC, Dicerna Pharmaceuticals, Inc., Sirnaomics, Inc., ProQR Therapeutics N.V., Silence Therapeutics PLC, CureVac N.V., Alnylam Pharmaceuticals, Inc., and Gotham Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the RNA Interference Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across dsRNA, miRNA, and siRNA.
• Based on Therapeutics, market is studied across Autoimmune Hepatitis, Hepatitis B and C, Neurological Disorders, Oncology, and Respiratory Disorders.
• Based on Application, market is studied across Drug Discovery and Development and Therapeutics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Prevalence of Genetic and Chronic Disorders Globally
    • 5.1.1.2. Increasing Application of RNAi Technology in Drug Discovery & Development
    • 5.1.1.3. Growing Need for Molecular Diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent FDA Regulations Regarding RNAi Therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing Research and Development in the Field of Nanotechnology and Cancer
    • 5.1.3.2. State-of-the-art RNAi Therapies in Development
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns in Delivery of RNA-Interference Therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: siRNA's use for targeted gene therapy for treating a multitude of diseases
  • 5.2.2. Application: Exponential adoption of RNA interference technology for dru discovery & development
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. RNA Interference Technology Market, by Type

• 6.1. Introduction
• 6.2. dsRNA
• 6.3. miRNA
• 6.4. siRNA

7. RNA Interference Technology Market, by Therapeutics

• 7.1. Introduction
• 7.2. Autoimmune Hepatitis
• 7.3. Hepatitis B and C
• 7.4. Neurological Disorders
• 7.5. Oncology
• 7.6. Respiratory Disorders

8. RNA Interference Technology Market, by Application

• 8.1. Introduction
• 8.2. Drug Discovery and Development
• 8.3. Therapeutics

9. Americas RNA Interference Technology Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific RNA Interference Technology Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa RNA Interference Technology Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Switch Therapeutics Launches with USD 52 Million to Advance First-of-its-Kind RNAi Technology
  • 12.3.2. Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

Companies Mentioned

• 1. Gradalis, Inc.
• 2. Arcturus Therapeutics Holdings Inc.
• 3. Merck KGaA
• 4. NeuBase Therapeutics, Inc.
• 5. Arrowhead Pharmaceuticals, Inc.
• 6. Novartis AG
• 7. Nutcracker Therapeutics, Inc.
• 8. Bioneer Corporation
• 9. Ionis Pharmaceuticals, Inc.
• 10. Arbutus Biopharma Corporation
• 11. AMSBIO
• 12. Atalanta Therapeutics
• 13. Phio Pharmaceuticals Corp.
• 14. Thermo Fisher Scientific Inc.
• 15. Sanofi S.A.
• 16. AstraZeneca PLC
• 17. Dicerna Pharmaceuticals, Inc.
• 18. Sirnaomics, Inc.
• 19. ProQR Therapeutics N.V.
• 20. Silence Therapeutics PLC
• 21. CureVac N.V.
• 22. Alnylam Pharmaceuticals, Inc.
• 23. Gotham Therapeutics Corp.